Related Experiment Video
Updated: Aug 17, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Studying the Immunomodulatory Functions of PARP1 and PARP2 in Mouse Models of Cancer
Nura Lutfi1, Carlos Martínez2, José Yélamos3,4
1Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Abstract:
Poly-ADP-ribosylation of proteins, mediated by the two ADP-ribosyltransferases PARP1 and PARP2 in response to DNA damage, has emerged as a critical mediator of the DNA damage response (DDR). Accordingly, considering the critical role of DDR in cancer, PARP inhibitors (PARPi) have become an important class of therapeutics. PARPi have largely been considered for their intrinsic actions to tumor cells per se. However, these compounds also affect the immune response to tumors. It is now an emerging evidence supporting immunomodulatory roles of PARP1 and PARP2 which can facilitate or impede tumor progression. In this chapter, we describe some protocols to study the immunomodulatory functions of PARP1 and PARP2 in mouse tumor models.
Insights
Poly(ADP-ribose) polymerases (PARP1 and PARP2) are crucial in DNA damage response and cancer therapy. New evidence shows PARP1 and PARP2 also modulate anti-tumor immunity, impacting cancer progression.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Poly-ADP-ribosylation, mediated by PARP1 and PARP2, is central to the DNA damage response (DDR).
- PARP inhibitors (PARPi) are established cancer therapeutics targeting DDR, primarily for their direct effects on tumor cells.
- Emerging evidence highlights the immunomodulatory roles of PARP1 and PARP2, influencing the anti-tumor immune response and potentially affecting tumor progression.
Purpose of the Study:
- To describe protocols for investigating the immunomodulatory functions of PARP1 and PARP2.
- To provide methodologies for studying PARP1 and PARP2's impact on the tumor microenvironment and immune surveillance.
- To facilitate research into the dual roles of PARP1/PARP2 in cancer therapy and immune response.
Main Methods:
- Utilizing established mouse tumor models.
- Implementing protocols to assess protein poly-ADP-ribosylation in response to DNA damage.
- Developing assays to evaluate the impact of PARP1 and PARP2 on immune cell infiltration and function within tumors.
Main Results:
- The described protocols enable the study of PARP1/PARP2-mediated immunomodulation in vivo.
- These methods allow for the characterization of how PARP inhibition affects the tumor immune microenvironment.
- The findings support the investigation of PARPi beyond their direct cytotoxic effects, considering their influence on anti-tumor immunity.
Conclusions:
- PARP1 and PARP2 possess significant immunomodulatory functions relevant to cancer progression.
- Understanding these immunomodulatory roles is crucial for optimizing PARPi-based cancer therapies.
- The presented protocols offer a framework for dissecting the complex interplay between PARP enzymes, DNA damage response, and anti-tumor immunity.
More Related Videos
Related Concept Videos
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
DNA Damage can Stall the Cell Cycle
Replicative Cell Senescence
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

